Finance

Beta
Lists
6949:TPE
Pell Bio Med Technology Co Ltd
NT$635.00
+0.63%
(+4.00) 1D
Jun 3, 1:30:35 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 6949...
Open
NT$634.00
High
NT$636.00
Low
NT$623.00
Mkt. cap
41.64B
Avg. vol.
205.18K
Volume
52.11K
52-wk high
NT$929.00
52-wk low
NT$125.92
EPS
-NT$7.05
Open
NT$634.00
High
NT$636.00
Low
NT$623.00
Mkt. cap
41.64B
Avg. vol.
205.18K
Volume
52.11K
52-wk high
NT$929.00
52-wk low
NT$125.92
EPS
-NT$7.05
News stories
From sources across the web
About Pell Bio Med Technology Co Ltd
CEO-
Employees-
Founded2017
Headquarters-
SectorBiotechnology
Websitepellbmt.com
Previous reportsAll values in TWD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TWD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.87M
7.54M
6.07M
6.37M
Cost of goods sold
9.18M
14.20M
4.72M
7.57M
Cost of revenue
9.18M
14.20M
4.72M
7.57M
Research and development expenses
45.36M
81.66M
74.30M
41.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.34M
37.02M
101.22M
46.01M
Operating expense
79.70M
118.68M
175.51M
87.55M
Total operating expenses
88.89M
132.87M
180.23M
95.12M
Operating income
-83.02M
-125.33M
-174.16M
-88.76M
Other non operating income
195.00K
147.00K
609.00K
478.00K
EBT including unusual items
-83.40M
-124.78M
-167.23M
-87.17M
EBT excluding unusual items
-82.84M
-124.78M
-167.23M
-87.17M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-77.80M
-118.41M
-151.96M
-76.58M
Net profit margin
-1,325.43%
-1,570.22%
-2,503.82%
-1,202.64%
Earnings per share
-
-
-
-
Interest and investment income
3.55M
1.46M
6.39M
2.05M
Interest expense
-1.46M
-1.43M
-
-943.00K
Net interest expenses
2.09M
27.00K
6.39M
1.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
-78.21M
-120.46M
-169.60M
-69.84M
Gain or loss from assets sale
-
-
-
-19.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer